Anti-NFAT5 antibody - N-terminal
1
(1 Review)
|
(3 Publications)
Rabbit Polyclonal NFAT5 antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Recombinant Fragment Protein within Human NFAT5 aa 100-450.
View Alternative Names
KIAA0827, TONEBP, NFAT5, Nuclear factor of activated T-cells 5, NF-AT5, T-cell transcription factor NFAT5, Tonicity-responsive enhancer-binding protein, TonE-binding protein, TonEBP
- WB
Unknown
Western blot - Anti-NFAT5 antibody - N-terminal (AB137407)
5% SDS PAGE
All lanes:
Western blot - Anti-NFAT5 antibody - N-terminal (ab137407) at 1/1000 dilution
All lanes:
MOLT4 whole cell lysate at 30 µg
Predicted band size: 165 kDa
false
- WB
CiteAb
Western blot - Anti-NFAT5 antibody - N-terminal (AB137407)
NFAT5 western blot using anti-NFAT5 antibody - N-terminal ab137407. Publication image and figure legend from Zhang, Y., Qian, X., et al., 2020, Theranostics, PubMed 31903118.
ab137407 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab137407 please see the product overview.
ASIC1a induces nuclear translocation of NFATc3 by mediating Ca2+ influx. (A) Semi-quantitative analysis of NFATc1-4 and NFAT5 expressions in human normal and RA synovial tissues by integral optical density (IOD). (B) Semi-quantitative analysis of NFATc1-4 and NFAT5 expressions in rat ankle synovium by integral optical density (IOD). (C) Western blot analysis of total, nuclear, and cytoplasmic NFATc1-4 and NFAT5 expressions in NSF and RASF. (D) Western blot analysis of total, nuclear, and cytoplasmic NFATc1-4 expressions in RASF in an acidic environment (pH 6.0). (E) Western blot analysis of total NFATc3 (tNFATc3), nuclear NFATc3 (nNFATc3), and cytoplasmic NFATc3 (cNFATc3) expression in RASF-ASIC1a transfectants treated with pH 6.0 for 6 h. (F) Western blot analysis of total NFATc3 (tNFATc3), nuclear NFATc3 (nNFATc3) and cytoplasmic NFATc3 (cNFATc3) expression in ASIC1a shRNA transfectants treated with pH 6.0 for 6 h. (G) Western blot analysis of Nuclear NFATc3 (nNFATc3) proteins in RASF with 1 mM EGTA, 10 μM BAPTA-AM, 5 μM verapamil and HMA. (H) Western blot analysis of total, nuclear and cytoplasmic NFATc1-4 proteins in with 100 nM PcTx-1 were used in the experiment. (I) Immunofluorescence analysis of NFATc1-4 expressions in RASF treated with pH 6.0 + 100 nM PcTx-1. The scale bars are 20 μm. (J) Immunofluorescence analysis of NFATc3 expression in RASF with 1 mM EGTA, 10 μM BAPTA-AM, 5 μM verapamil and HMA. The scale bars are 20 μm. (K) Immunohistochemistry analysis of NFATc3 expression in rat ankle synovium on day 41 (n = 8). Student´s t-test or one-way ANOVA was used for statistical analysis, and data are expressed as mean ± SEM for three separate experiments.
false
Reactivity data
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
NFAT5 helps regulate the cellular response to hypertonic stress in several tissues including the kidneys brain and immune cells. It acts as a transcriptional activator that induces the expression of osmoprotective genes such as the sodium/myo-inositol transporter and aldose reductase. NFAT5 functions not as part of a larger complex but as an independent transcription factor which directly binds to enhancers within target gene promotors playing a critical role in cellular adaptation to hyperosmotic conditions.
Pathways
NFAT5 plays a significant role in the hypertonicity-induced signaling pathway and the osmoprotective pathway. Through these it influences key cellular processes by modulating the transcription of genes necessary for adaptation to osmotic stress. It stands in relation to other NFAT family members like NFATc1 and NFATc2 but distinctively differs as it does not rely directly on calcium and calcineurin for its activation unlike its relatives involved in the calcineurin/NFAT pathway.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (3)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in endocrinology 12:573143 PubMed33776905
2021
Applications
Unspecified application
Species
Unspecified reactive species
Theranostics 10:247-264 PubMed31903118
2020
Applications
Unspecified application
Species
Unspecified reactive species
Oncotarget 8:11173-11186 PubMed28061436
2017
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com